Bristol-Myers Squibb unveils new executive appointment

Bristol-Myers Squibb (BMS) has unveiled a new appointment within its Global Clinical Research, Neuroscience department.

It has been announced Dr Howard Feldman will join the firm’s research and development team as vice-president and therapeutic area head – reporting to its vice-president of neuroscience and virology, Dr Doug Manion.

After receiving his medical degree in 1978, Dr Feldman has gone on to work in a number of areas relating to the field of frontotemporal dementia – including a period as part of the team that discovered the progranulin gene as a cause of the condition.

Having published over 100 peer-reviewed papers and been in receipt of a number of accolades for his work, BMS’ senior vice-president of global development and medical affairs Brian Daniels said he was confident about the appointment.

“Howard’s renowned expertise in behavioural neurology and Alzheimer’s disease will help ensure we remain a leader in helping patients prevail against serious disease, specifically neurological and psychiatric disorders,” he said.

Last month, BMS declared its quarterly dividend, revealing a figure of $0.31 (0.20 pounds) per share on the $0.10 par value of its common stock. The dividend is set to be paid out to holders of stock on February 2nd.